みんなで解決！　病棟のギモン

出版社： 羊土社
著者：
発行日： 2020-03-20
分野： 医学一般  >  医学一般
ISBN： 9784758118675
電子書籍版： 2020-03-20 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,290 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,290 円(税込)

購入する

商品紹介

レジデントノートの人気連載がパワーアップ！ルーチン処方は必要？検査の使いどきは？など内科研修で誰もが抱く身近な疑問を会話形式でやさしく解説．疑問を自分で解決するプロセスやエビデンスの活かし方も学べる．

目次

  • 第１章　総合内科病棟のギモン
    Q1 “かぜ”症状の患者さんにどう対応する？
    Q2　風邪の患者さんに何を処方する？
    Q3　熱を下げるにはどのクスリを使うのがいい？
    Q4　脱水をどう評価する？ 補液の一歩目は何がいい？
    Q5　浮腫はどうマネジメントすればいい？
    Q6　睡眠薬はどう使うのがいい？
    Q7　X線やCT検査前に妊娠反応検査は必ず必要？
    Q8　確実な静脈路確保のコツを教えて！

    第２章　呼吸器・循環器病棟のギモン
    Q9　喀痰抗酸菌塗抹検査が陽性になったらどうする？
    Q10　深部静脈血栓症ってそんなに大事？
    Q11　胸水貯留，すぐ抜くべき？ 何を調べる？
    Q12　酸素療法の使い分けがわからない！
    Q13　Door-to-Balloon timeってなに？
    Q14　利尿薬は腎臓に悪い？急性心不全の腎うっ血とは？
    Q15　慢性期も利尿薬を使いすぎると予後を悪くするって本当？
    Q16　手技や手術前に抗血栓薬は休薬すべき？

    第３章　腎臓・内分泌内科病棟のギモン
    Q17　高血圧の治療はいつから開始すればよいの？
    Q18　二次性高血圧は，いつ調べるの？
    Q19　高血圧の食事療法・運動療法をどう進める？
    Q20　入院患者の低カリウム血症をどうマネジメントすべき？
    Q21　急性腎障害への血液透析，いつ導入するの？
    Q22　なぜメトホルミンばかり使われるの？
    Q23　血糖値を下げたい，けど網膜症の進行は大丈夫？
    Q24　糖尿病患者の周術期の血糖管理ってそんなに大事なの？

    第４章　感染・膠原病・血液病棟のギモン
    Q25　グラム染色の使いどきって？
    Q26　血液培養はどうやって，どのくらいとればいい？
    Q27　入院患者の発熱にどう対応する？
    Q28　海外から帰国後の発熱にどう対応する？
    Q29　抗核抗体が陽性！どうすればいい？
    Q30　ステロイドの使い方がよくわからない
    Q31　ステロイドのリスクや副作用って？
    Q32　ST合剤の使いどころって？
    Q33　血球減少にどう対応すべき？

    第５章　消化器・神経病棟のギモン
    Q34　整腸剤はどういうときに使うの？
    Q35　入院中に軽度肝障害が出現した患者さんは退院できる？
    Q36　胃薬は何のために処方するの？
    Q37　高齢患者の便潜血検査をどう考える？
    Q38　入院患者がせん妄に！どう対応する？
    Q39　失神へのアプローチがよくわからない
    Q40　救急でてんかん重積にどう対応する？
    Q41　慢性頭痛へのアプローチを知りたい

    第６章　研修医室のギモン
    Q42　そもそもなんで研修医が論文を読まないといけないの？
    Q43　では論文はどう探せばいいの？
    Q44　実践EBM(1)：コーヒーは健康にいいの？
    Q45　実践EBM(2)：腫瘍マーカーってスクリーニングに使えるの？
    Q46　調べたことのプレゼンテーションってどうやればいいの？
    Q47　悪いニュースをどう伝える？

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 総合内科病棟のギモン

P.17 掲載の参考文献
1) Meropol SB, et al:Risks and benefits associated with antibiotic use for acute respiratory infections:a cohort study. Ann Fam Med, 11:165-172, 2013
PubMed
2) Chen TC, et al:Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis:a systematic review and meta-analysis. Int J Infect Dis, 15:e211-e216, 2011
PubMed
3) 厚生労働省健康局結核感染症課:抗微生物薬適正使用の手引き 第二版, 2019 [https://www.mhlw.go.jp/content/10900000/000573655.pdf](2020年1月閲覧)
 
4) Harris AM, et al:Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults:Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med, 164:425-434, 2016
PubMed
5) Gwaltney JM Jr, et al:Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA, 202:494-500, 1967
 
P.23 掲載の参考文献
1) Mangione-Smith R, et al:Communication practices and antibiotic use for acute respiratory tract infections in children. Ann Fam Med, 13:221-227, 2015
PubMed
2) Gwaltney JM Jr, et al:Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA, 202:494-500, 1967
 
3) 厚生労働省健康局結核感染症課:抗微生物薬適正使用の手引き 第二版, 2019 [https://www.mhlw.go.jp/content/10900000/000573655.pdf](2020年1月閲覧)
 
4) De Sutter AI, et al:Antihistamines for the common cold. Cochrane Database Syst Rev:CD009345, 2015
PubMed
5) Deckx L, et al:Nasal decongestants in monotherapy for the common cold. Cochrane Database Syst Rev:CD009612, 2016
PubMed
6) Li S, et al:Acetaminophen(paracetamol)for the common cold in adults. Cochrane Database Syst Rev:CD008800, 2013
PubMed
7) Kim SY, et al:Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev:CD006362, 2015
PubMed
8) Smith SM, et al:Over-the-counter(OTC)medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev:CD001831, 2014
PubMed
9) Malesker MA, et al:Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold:CHEST Expert Panel Report. Chest, 152:1021-1037, 2017
 
10) Becker LA, et al:Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. Cochrane Database Syst Rev:CD001726, 2015
 
11) 日本小児科学会:インフルエンザ脳炎・脳症における解熱剤の影響について, 2000 [https://www.jpeds.or.jp/modules/activity/index.php?content_id=201](2020年1月閲覧)
 
12) Sullivan JE, et al:Fever and antipyretic use in children. Pediatrics, 127:580-587, 2011
PubMed
13) Fever in under 5s:assessment and initial management. NICE guidelines, 2013 [https://www.nice.org.uk/guidance/cg160](2019年12月閲覧)
 
14) Hayward G, et al:Corticosteroids for the common cold. Cochrane Database Syst Rev:CD008116, 2015
PubMed
15) Yoshino T, et al:The use of maoto (Ma-Huang-Tang), a traditional Japanese Kampo medicine, to alleviate flu symptoms:a systematic review and meta-analysis. BMC Complement Altern Med, 19:68, 2019
 
16) Wang C, et al:Oseltamivir compared with the chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza:a randomized trial. Ann Intern Med, 155:217-225, 2011
PubMed
P.29 掲載の参考文献
1) 「内科レジデントマニュアル 第9版」(聖路加国際病院内科専門研修委員会/編), 医学書院, 2019
 
2) 「ワシントンマニュアル 第13版」(高久史麿, 他/監訳), メディカル・サイエンス・インターナショナル, 2015
 
3) 「ハリソン内科学 第5版」(福井次矢, 他/日本語版監修), メディカル・サイエンス・インターナショナル, 2017
 
4) Young P, et al:Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med, 373:2215-2224, 2015
PubMed
P.37 掲載の参考文献
1) 「マクギーのフィジカル診断学 原著第4版」(McGEE S/著, 徳田安春/総監訳), 診断と治療社, 2019
 
2) Hartling L, et al:Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst Rev:CD004390, 2006
PubMed
3) Yunos NM, et al:Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA, 308:1566-1572, 2012
PubMed
4) Young P, et al:Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit:The SPLIT Randomized Clinical Trial. JAMA, 314:1701-1710, 2015
PubMed
5) Finfer S, et al:A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med, 350:2247-2256, 2004
PubMed
6) Frost P:Intravenous fluid therapy in adult inpatients. BMJ, 350:g7620, 2015
PubMed
P.38 掲載の参考文献
1) Freedman SB, et al:JAMA, 315:1966-1974, 2016
PubMed
2) Rhodes A, et al:Crit Care Med, 45:486-552, 2017
PubMed
3) Semler MW, et al:N Engl J Med, 378:829-839, 2018
PubMed
4) Lobo DN & Awad S:Kidney Int, 86:1096-1105, 2014
PubMed
P.48 掲載の参考文献
1) 「Robbins & Cotran Pathologic Basis of Disease 9th Edition」(Vinay Kumar, et al), Elsevier, 2014
 
2) Sterns RH:Pathophysiology and etiology of edema in adults. UpToDate, 2018
 
3) Lai WM, et al:A triphasic theory for the swelling and deformation behaviors of articular cartilage. J Biomech Eng, 113:245-258, 1991
PubMed
4) Bhave G & Neilson EG:Body fluid dynamics:back to the future. J Am Soc Nephrol, 22:2166-2181, 2011
 
5) 多田羅恒雄:総論 1. 侵襲時輸液の生理学 知っておきたい体液動態. 「特集 輸液・ボリューム管理」, INTENSIVIST, 9:259-271, 2017
 
6) Sterns RH:General principles of the treatment of edema in adults. UpToDate, 2018
 
7) Stampfer M, et al:Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation, 37:900-911, 1968
PubMed
8) 安村 敏, 他:科学的根拠に基づいたアルブミン製剤の使用ガイドライン(第2版), 日本輸血細胞治療学会誌, 64:700-717, 2018
Medical*Online
9) Kitsios GD, et al:Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia:a meta-analysis. J Crit Care, 29:253-259, 2014
PubMed
P.55 掲載の参考文献
1) Lemola S, et al:Adolescents' electronic media use at night, sleep disturbance, and depressive symptoms in the smartphone age. J Youth Adolesc, 44:405-418, 2015
 
2) Chang AM, et al:Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. Proc Natl Acad Sci U S A, 112:1232-1237, 2015
PubMed
3) Burkhart K & Phelps JR:Amber lenses to block blue light and improve sleep:a randomized trial. Chronobiol Int, 26:1602-1612, 2009
PubMed
4) Gringras P, et al:Bigger, Brighter, Bluer-Better? Current Light-Emitting Devices -Adverse Sleep Properties and Preventative Strategies. Front Public Health, 3:233, 2015
PubMed
5) Lawrenson JG, et al:The effect of blue-light blocking spectacle lenses on visual performance, macular health and the sleep-wake cycle:a systematic review of the literature. Ophthalmic Physiol Opt, 37:644-654, 2017
PubMed
6) 健康づくりのための睡眠指針 2014～睡眠12箇条～ [https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000047221.pdf](2020年1月閲覧)
 
7) Gray SL, et al:Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc, 54:224-230, 2006
PubMed
8) Tom SE, et al:Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury. Sleep, 39:1009-1014, 2016
PubMed
9) 厚生労働科学研究・障害者対策総合研究事業「睡眠薬の適正使用及び減量・中止のための診療ガイドラインに関する研究班」および日本睡眠学会・睡眠薬使用ガイドライン作成ワーキンググループ:睡眠薬の適正な使用と休薬のための診療ガイドライン. 2013 [http://www.jssr.jp/data/pdf/suiminyaku-guideline.pdf](2020年1月閲覧)
 
10) Kan CC, et al:Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry, 45:88-94, 2004
PubMed
11) Markota M, et al:Benzodiazepine Use in Older Adults:Dangers, Management, and Alternative Therapies. Mayo Clin Proc, 91:1632-1639, 2016
PubMed
12) Rickels K, et al:Long-term diazepam therapy and clinical outcome. JAMA, 250:767-771, 1983
PubMed
P.61 掲載の参考文献
1) 産婦人科診療ガイドライン-産科編2017. 日本産科婦人科学会/日本産婦人科医会, 2014 [http://www.jsog.or.jp/activity/pdf/gl_sanka_2017.pdf](2020年1月閲覧)
 
2) Kusama T & Ota K:Radiological protection for diagnostic examination of pregnant women. Congenit Anom(Kyoto), 42:10-14, 2002
PubMed
3) ICRP:Pregnancy and medical radiation. ICRP Publication 84, Ann ICRP, 30, 2000 (Committee report)
 
P.66 掲載の参考文献
1) Jacobson AF & Winslow EH:Variables influencing intravenous catheter insertion difficulty and failure:an analysis of 339 intravenous catheter insertions. Heart Lung, 34:345-359, 2005
PubMed
2) Wallis MC, et al:Risk factors for peripheral intravenous catheter failure:a multivariate analysis of data from a randomized controlled trial. Infect Control Hosp Epidemiol, 35:63-68, 2014
PubMed
3) 五味敏昭:安全・確実な静脈採血(肘窩)に必要な解剖学の知識. Medical Technology, 38:14-20, 2010
Medical*Online

第2章 呼吸器・循環器病棟のギモン

P.73 掲載の参考文献
1) Dharmadhikari AS, et al:Surgical face masks worn by patients with multidrug-resistant tuberculosis:impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med, 185:1104-1109, 2012
 
2) Perez-Guzman C, et al:Does aging modify pulmonary tuberculosis ?:A meta-analytical review. Chest, 116:961-967, 1999
PubMed
3) 「結核診療ガイドライン 改訂第3版」(日本結核学会/編), 南江堂, 2015
 
4) Kenyon TA, et al:Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med, 334:933-938, 1996
PubMed
5) 「感染症法に基づく結核の接触者健康診断の手引き 改訂第5版」(厚生労働科学研究 地域における効果的な結核対策の強化に関する研究, 研究代表者/石川信克, 研究分担者/阿彦忠之), 2014 [http://www.jata.or.jp/rit/rj/2014.3sessyokusya1.pdf](2020年1月閲覧)
 
P.81 掲載の参考文献
1) 日本医療安全調査機構:急性肺血栓塞栓症に係る死亡事例の分析, 2017 [https://www.medsafe.or.jp/uploads/uploads/files/teigen-02.pdf](2020年1月閲覧)
 
2) 日本循環器学会:肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン(2017年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2017_ito_h.pdf](2020年1月閲覧)
 
3) Dennis M, et al:Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke(CLOTS trial 1):a multicentre, randomised controlled trial. Lancet, 373:1958-1965, 2009
PubMed
4) Raskob GE, et al:Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med, 378:615-624, 2018
PubMed
5) Chang SL, et al:Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. JAMA, 319:807-817, 2018
PubMed
6) Yamashita Y, et al:Asymptomatic Lower Extremity Deep Vein Thrombosis-Clinical Characteristics, Management Strategies, and Long-Term Outcomes. Circ J, 81:1936-1944, 2017
PubMed
P.89 掲載の参考文献
1) Sahn SA & Light RW:The sun should never set on a parapneumonic effusion. Chest, 95:945-947, 1989
PubMed
2) Light RW, et al:Pleural effusions:the diagnostic separation of transudates and exudates. Ann Intern Med, 77:507-513, 1972
PubMed
3) Light RW:Clinical practice. Pleural effusion. N Engl J Med, 346:1971-1977, 2002
PubMed
4) Light RW:A new classification of parapneumonic effusions and empyema. Chest, 108:299-301, 1995
PubMed
5) Aggarwal AN, et al:Adenosine deaminase for diagnosis of tuberculous pleural effusion:A systematic review and meta-analysis. PLoS One, 14:e0213728, 2019
PubMed
6) Porcel JM:Identifying transudates misclassified by Light's criteria. Curr Opin Pulm Med, 19:362-367, 2013
 
7) Bielsa S, et al:Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. Respirology, 17:721-726, 2012
 
P.98 掲載の参考文献
1) 倉原 優:酸素療法の実際:「とりあえず酸素を流せばよい」というわけではない!;特集呼吸器疾患2. Hospitalist, 5:378-386, 2017
 
2) Dysart K, et al:Research in high flow therapy:mechanisms of action. Respir Med, 103:1400-1405, 2009
PubMed
3) Maggiore SM, et al:Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med, 190:282-288, 2014
PubMed
4) Hernandez G, et al:Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients:A Randomized Clinical Trial. JAMA, 315:1354-1361, 2016
PubMed
5) Hernandez G, et al:Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients:A Randomized Clinical Trial. JAMA, 316:1565-1574, 2016
PubMed
P.104 掲載の参考文献
1) Thygesen K, et al:Fourth Universal Definition of Myocardial Infarction(2018). Circulation, 138:e618-651, 2018
PubMed
2) Berger PB, et al:Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction:results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation, 100:14-20, 1999
PubMed
3) Brodie BR, et al:When is door-to-balloon time critical? Analysis from the HORIZONS-AMI(Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC(Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol, 56:407-413, 2010
PubMed
4) O'Gara PT, et al:2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 61:e78-140, 2013
 
5) Ibanez B, et al:2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 39:119-177, 2018
 
6) 日本循環器学会 2017-2018年度活動:急性冠症候群診療ガイドライン(2018年改訂版), 2019 [http://www.j-circ.or.jp/guideline/pdf/JCS2018_kimura.pdf](2020年1月閲覧)
 
7) Bradley EH, et al:Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med, 355:2308-2320, 2006
PubMed
8) Menees DS, et al:Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med, 369:901-909, 2013
PubMed
9) Shiomi H, et al:Association of onset to balloon and door to balloon time with long term clinical outcome in patients with ST elevation acute myocardial infarction having primary percutaneous coronary intervention:observational study. BMJ, 344:e3257, 2012
PubMed
10) Barnes GD, et al:False activation of the cardiac catheterization laboratory for primary PCI. Am J Manag Care, 19:671-675, 2013
 
P.111 掲載の参考文献
1) Nohria A, et al:Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol, 41:1797-1804, 2003
PubMed
2) Damman K, et al:Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol, 53:582-588, 2009
 
3) Mullens W, et al:Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol, 53:589-596, 2009
PubMed
4) Matsue Y, et al:Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol, 69:3042-3051, 2017
PubMed
5) Afsar B, et al:Focus on renal congestion in heart failure. Clin Kidney J, 9:39-47, 2016
PubMed
P.118 掲載の参考文献
1) Yancy CW, et al:2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 128:e240-e327, 2013
 
2) Eshaghian S, et al:Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol, 97:1759-1764, 2006
PubMed
3) Gheorghiade M, et al:Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure:the EVEREST Clinical Status Trials. JAMA, 297:1332-1343, 2007
PubMed
4) Konstam MA, et al:Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial. JAMA, 297:1319-1331, 2007
PubMed
5) Pitt B, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 341:709-717, 1999
 
6) Juurlink DN, et al:Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med, 351:543-551, 2004
PubMed
P.119 掲載の参考文献
1) Abraham WT, et al:Lancet, 387:453-461, 2016
PubMed
2) Desai AS, et al:J Am Coll Cardiol, 69:2357-2365, 2017
PubMed
P.125 掲載の参考文献
1) Lip GY, et al:Identifying patients at high risk for stroke despite anticoagulation:a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke, 41:2731-2738, 2010
 
2) Gage BF, et al:Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation. JAMA, 285:2864-2870, 2001
 
3) Douketis JD, et al:Perioperative management of antithrombotic therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141:e326S-e350S, 2012
PubMed
4) Lip GY, et al:Perioperative management of patients receiving anticoagulants. UpTo-Date, 2019
 
5) 藤本一眞, 他:抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌, 54:2075-2102, 2012
 
6) Flaker GC, et al:Management of Periprocedural Anticoagulation:A Survey of Contemporary Practice. J Am Coll Cardiol, 68:217-226, 2016
PubMed
7) Siegal D, et al:Periprocedural heparin bridging in patients receiving vitamin K antagonists:systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation, 126:1630-1639, 2012
PubMed
8) Douketis JD, et al:Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med, 373:823-833, 2015
PubMed
9) 加藤元嗣, 他:抗血栓薬服用患者に対する消化器内視鏡診療ガイドライン 直接経口抗凝固薬(DOAC)を含めた抗凝固薬に関する追補2017. 日本消化器内視鏡学会雑誌, 59(7):1547-1558, 2017
 

第3章 腎臓・内分泌内科病棟のギモン

P.132 掲載の参考文献
1) Whelton PK, et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 71:e127-248, 2018
 
2) 「高血圧治療ガイドライン2019」(日本高血圧学会高血圧治療ガイドライン作成委員会/編), ライフサイエンス出版, 2019
 
3) Miura K, et al:Epidemiology of Hypertension in Japan:where are we now? Circ J, 77:2226-2231, 2013
PubMed
4) Rapsomaniki E, et al:Blood pressure and incidence of twelve cardiovascular diseases:lifetime risks, healthy life-years lost, and age-specific associations in 1・25 million people. Lancet, 383:1899-1911, 2014
 
5) Poulter NR, et al:Hypertension. Lancet, 386:801-812, 2015
PubMed
6) Muntner P, et al:Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation, 137:109-118, 2018
PubMed
7) Wright JT Jr, et al:A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373:2103-2116, 2015
PubMed
8) Ettehad D, et al:Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis. Lancet, 387:957-967, 2016
 
9) 日本老年医学会:高齢者高血圧診療ガイドライン2017. 日本老年医学会雑誌, 54:236-298, 2017
 
10) Williamson JD, et al:Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >- 75 Years:A Randomized Clinical Trial. JAMA, 315:2673-2682, 2016
 
11) Myers MG, et al:Automated office blood pressure measurement in primary care. Can Fam Physician, 60:127-132, 2014
PubMed
P.141 掲載の参考文献
1) 「高血圧治療ガイドライン 2019」(日本高血圧学会高血圧治療ガイドライン作成委員会/編), ライフサイエンス出版, 2019
 
2) Mulatero P, et al:Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab, 89:1045-1050, 2004
PubMed
3) Funder JW, et al:The Management of Primary Aldosteronism:Case Detection, Diagnosis, and Treatment:An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 101:1889-1916, 2016
PubMed
4) 「わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント」(日本内分泌学会「原発性アルドステロン症ガイドライン実施の実態調査と普及に向けた標準化に関する検討」委員会/編), 診断と治療社, 2016
 
5) Monticone S, et al:Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension:a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 6:41-50, 2018
PubMed
6) Whelton PK, et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71:e13-115, 2017
 
7) Rossi GP, et al:Renovascular hypertension with low-to-normal plasma renin:clinical and angiographic features. Clin Sci(Lond), 93:435-443, 1997
PubMed
8) Cooper CJ, et al:Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med, 370:13-22, 2014
PubMed
9) Unger N, et al:Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol, 154:409-417, 2006
PubMed
10) Calhoun DA, et al:Resistant hypertension:diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 51:1403-1419, 2008
PubMed
P.151 掲載の参考文献
1) Whelton PK, et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 71:e127-248, 2018
 
2) 「高血圧治療ガイドライン2019」(日本高血圧学会高血圧治療ガイドライン作成委員会/編), ライフサイエンス出版, 2019
 
3) OLDWAYS ASIAN DIET:[https://oldwayspt.org/system/files/atoms/files/Asian_pyramid_flyer_0.pdf] (2020年1月閲覧)
 
4) OLDWAYS MEDITERRANEAN DIET:[https://oldwayspt.org/system/files/atoms/files/OW_MedPyramid_HiResLetter.pdf] (2019年12月閲覧)
 
5) Appel LJ, et al:A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med, 336:1117-1124, 1997
 
6) Sofi F, et al:Adherence to Mediterranean diet and health status:meta-analysis. BMJ, 337:a1344, 2008
PubMed
7) Huedo-Medina TB, et al:Methodologic quality of meta-analyses and systematic reviews on the Mediterranean diet and cardiovascular disease outcomes:a review. Am J Clin Nutr, 103:841-850, 2016
PubMed
8) Taylor RS, et al:Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev, CD009217, 2011
 
9) Taylor RS, et al:Reduced dietary salt for the prevention of cardiovascular disease:a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens, 24:843-853, 2011
PubMed
10) He FJ & MacGregor GA:Salt reduction lowers cardiovascular risk:meta-analysis of outcome trials. Lancet, 378:380-382, 2011
PubMed
11) Cook NR, et al:Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention. J Am Coll Cardiol, 68:1609-1617, 2016
PubMed
12) Mente A, et al:Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension:a pooled analysis of data from four studies. Lancet, 388:465-475, 2016
PubMed
13) Johnson BT, et al:Methodological quality of meta-analyses on the blood pressure response to exercise:a review. J Hypertens, 32:706-723, 2014
PubMed
14) Blumenthal JA, et al:Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure:the ENCORE study. Arch Intern Med, 170:126-135, 2010
PubMed
15) Collins R, et al:Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure:overview of randomised drug trials in their epidemiological context. Lancet, 335:827-838, 1990
PubMed
P.158 掲載の参考文献
1) Nyirenda MJ, et al:Hyperkalaemia. BMJ, 339:b4114, 2009
PubMed
2) Gennari FJ:Hypokalemia. N Engl J Med, 339:451-458, 1998
PubMed
3) 厚生労働省:平成29年 国民健康・栄養調査結果の概要, 2018 [https://www.mhlw.go.jp/content/10904750/000351576.pdf](2020年1月閲覧)
 
4) Palmer BF:A Physiologic-Based Approach to the Evaluation of a Patient With Hypokalemia. Am J Kidney Dis, 556:1184-1190, 2010
 
5) Lin SH, et al:Laboratory Tests to Determine the Cause of Hypokalemia and Paralysis. Arch Intern Med, 164:1561-1566, 2004
PubMed
P.163 掲載の参考文献
1) 「急性腎障害のためのKDIGO 診療ガイドライン」(日本腎臓学会/KDIGOガイドライン全訳版作成ワーキングチーム/監訳), 東京医学社, 2014
 
2) Gaudry S, et al:Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med, 375:122-133, 2016
PubMed
3) Zarbock A, et al:Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury:The ELAIN Randomized Clinical Trial. JAMA, 315:2190-2199, 2016
PubMed
P.164 掲載の参考文献
1) Fayad AII, et al:Cochrane Database Syst Rev, 12:CD010612, 2018
PubMed
2) Barbar SD, et al:N Engl J Med, 379:1431-1442, 2018
PubMed
P.171 掲載の参考文献
1) 「糖尿病治療ガイド2018-2019」(日本糖尿病学会/編著), 文光堂, 2018
 
2) 「糖尿病診療ガイドライン2019」(日本糖尿病学会/編著), 南江堂, 2019
 
3) Gerstein HC, et al:Effects of intensive glucose lowering in type 2 diabetes. NEJM, 358:2545-2559, 2008
PubMed
4) Boussageon R, et al:Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes:meta-analysis of randomised controlled trials. BMJ, 343:d4169, 2011
PubMed
5) Lipska KJ & Krumholz HM:Is Hemoglobin A1c the Right Outcome for Studies of Diabetes ? JAMA, 317:1017-1018, 2017
PubMed
6) Shichiri M, et al:Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23:B21-29, 2000
 
7) 日本糖尿病・生活習慣病ヒューマンデータ学会:糖尿病標準診療マニュアル(一般診療所・クリニック向け) 第15版, 2019 [http://human-data.or.jp/wp/wp-content/uploads/2019/04/DMmanual_15_190314.pdf](2019年12月閲覧)
 
8) Zinman B, et al:Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med, 373:2117-2128, 2015
PubMed
9) Marso SP, et al:Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 375:311-322, 2016
PubMed
10) American Diabetes Association:Standards of Medical Care in Diabetes-2019. Diabetes Care, 42(Suppl1), 2017
 
P.172 掲載の参考文献
1) Cosentino F, et al:Eur Heart J, 41:255-323, 2020
PubMed
2) Zweck E, et al:N Engl J Med, 381:2075-2076, 2019
PubMed
3) Christou GA, et al:Obes Rev, 20:805-815, 2019
PubMed
4) McMurray JJV, et al:N Engl J Med, 381:1995-2008, 2019
PubMed
5) 「最新 糖尿病診療のエビデンス 改訂版」 (能登 洋/著), 日経BP, 2019
 
P.177 掲載の参考文献
1) 「糖尿病診療ガイドライン2016」(日本糖尿病学会/ 編), 南江堂, 2016
 
2) 「Dr. 坂根のやる気がわいてくる糖尿病ケア」(坂根直樹/著), 医歯薬出版, 2009
 
3) Klupp NL, et al:Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors, Cochrane Database Syst Rev:CD007259, 2015
PubMed
4) Gibbons CH & Freeman R:Treatment-induced neuropathy of diabetes:an acute, iatrogenic complication of diabetes. Brain, 138:43-52, 2015
PubMed
5) Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977-986, 1993
 
6) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.Arch Ophthalmol, 116:874-886, 1998
PubMed
7) 森田千尋, 他:急激な血糖コントロールの網膜症に及ぼす影響-内科の立場より-. Diabetes Journal:糖尿病と代謝, 20:7-12, 1992
 
8) 船津英陽:血糖コントロールの指標からみた網膜症. 眼科, 36:765-779, 1994
 
9) Chodosh J, et al:Meta-analysis:chronic disease self-management programs for older adults. Ann Intern Med, 143:427-438, 2005
PubMed
10) American Diabetes Association:11. Microvascular Complications and Foot Care:Standards of Medical Care in Diabetes-2019. Diabetes Care, 42:S124-S138, 2019
PubMed
11) Ghanchi F:The Royal College of Ophthalmologists' clinical guidelines for diabetic retinopathy:a summary. Eye (Lond), 27:285-287, 2013
PubMed
12) Feldman-Billard S, et al:Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab, 44:4-14, 2018
PubMed
P.178 掲載の参考文献
1) 「糖尿病診療ガイドライン2019」(日本糖尿病学会/編・著), 南江堂, 2019
 
P.186 掲載の参考文献
1) Frisch A, et al:Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care, 33:1783-1788, 2010
PubMed
2) 「糖尿病専門医研修ガイドブック 改訂第7版」(日本糖尿病学会/編著), 診断と治療社, 2017
 
3) Miller ME, et al:Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 358:2545-2559, 2008
PubMed
4) van den Berghe G, et al:Intensive insulin therapy in critically ill patients. N Engl J Med, 345:1359-1367, 2001
PubMed
5) NICE-SUGAR Study Investigators:Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 360:1283-1297, 2009
 
6) 稲石 淳, 他:内分泌疾患の周術期 (1)糖尿病・血糖コントロール. Hospitalist, 4:335-343, 2016
 
7) Umpierrez G, et al:Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery:GLUCO-CABG Trial. Diabetes Care, 38:1665-1672, 2015
PubMed
8) Kansagara D, et al:Intensive insulin therapy in hospitalized patients:a systematic review. Ann Intern Med, 154:268-282, 2011
PubMed

第4章 感染・膠原病・血液病棟のギモン

P.193 掲載の参考文献
1) Fukuyama H, et al:Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia:a prospective observational study. BMC Infect Dis, 18:534, 2014
 
P.198 掲載の参考文献
1) Septimus E:Collecting Cultures:a Clinician Guide. Centers for Disease Control and Prevention [https://www.cdc.gov/antibiotic-use/core-elements/collecting-cultures.html](2020年1月閲覧)
 
2) 「Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed.」(Bennett JE, et al, eds), Elsevier, 2019
 
3) Miller JM, et al:A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases:2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis, 67:e1-e94, 2018
 
4) Kim NH, et al:Effect of routine sterile gloving on contamination rates in blood culture:a cluster randomized trial. Ann Intern Med, 154:145-151, 2011
PubMed
5) Falagas ME, et al:Comparison of utility of blood cultures from intravascular catheters and peripheral veins:a systematic review and decision analysis. J Med Microbiol, 57:1-8, 2008
PubMed
6) Salazar Mallen M, et al:Comparative study of blood cultures made from artery, vein, and bone marrow in patients with subacute bacterial endocarditis. Am Heart J, 33:692-695, 1947
PubMed
7) Lee A, et al:Detection of bloodstream infections in adults:how many blood cultures are needed? J Clin Microbiol, 45:3546-3548, 2007
PubMed
8) Spitalnic SJ, et al:The significance of changing needles when inoculating blood cultures:a meta-analysis. Clin Infect Dis, 21:1103-1106, 1995
PubMed
P.205 掲載の参考文献
1) Safdar N & Maki DG:Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. Crit Care Med, 30:2632-2635, 2002
PubMed
2) Magill SS, et al:Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 370:1198-1208, 2014
PubMed
P.213 掲載の参考文献
1) 日本政府観光局:年別 訪日外客数, 出国日本人数の推移. [https://www.jnto.go.jp/jpn/statistics/marketingdata_outbound.pdf](2019年12月閲覧)
 
2) Leder K, et al:GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med, 158:456-468, 2013
PubMed
3) 「Travel Medicine 3rd Edition」(Keystone JS, et al, eds), Elsevier, 2012
 
P.222 掲載の参考文献
1) Terao C, et al:Association between antinuclear antibodies and the HLA class II locus and heterogeneous characteristics of staining patterns:the Nagahama study. Arthritis Rheumatol, 66:3395-3403, 2014
PubMed
2) Satoh M, et al:Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum, 64:2319-2327, 2012
PubMed
3) 三森経世:自己抗体(抗核抗体, リウマトイド因子). 内科, 118:555-558, 2016
 
4) Pisetsky DS:Antinuclear antibody testing-misunderstood or misbegotten ? Nat Rev Rheumatol, 13:495-502, 2017
PubMed
P.232 掲載の参考文献
1) 「一冊できわめる ステロイド診療ガイド」(田中廣壽/他, 編), 文光堂, 2015
 
2) 「リウマチ・膠原病診療ゴールデンハンドブック」(竹内 勤/編), 南江堂, 2017
 
3) 「ステロイドのエビデンス」(川合眞一/編), 羊土社, 2015
 
4) Global Initiative for Asthma(GINA) [http://ginasthma.org]
 
5) 「喘息予防・管理ガイドライン 2018」(一般社団法人日本アレルギー学会喘息ガイドライン専門部会/監), 協和企画, 2018
 
6) Rowe BH, et al:Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev:CD002178, 2001
PubMed
7) Cathcart ES, et al:Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet, 1:163-166, 1976
PubMed
8) Mackworth-Young CG, et al:A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis, 47:496-502, 1988
PubMed
P.241 掲載の参考文献
1) Ruiz-Irastorza G, et al:Glucocorticoid use and abuse in SLE. Rheumatology, 51:1145-1153, 2012
PubMed
2) 日本骨代謝学会ステロイド性骨粗鬆症の管理と治療ガイドライン改訂委員会:ステロイド性骨粗鬆症の管理と治療ガイドライン 2014年改訂版, 2014 [http://jsbmr.umin.jp/guide/pdf/gioguideline.pdf](2020年1月閲覧)
 
3) Nawata H, et al:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab, 23:105-109, 2005
PubMed
4) 後藤由夫, 他:ステロイド糖尿病. 糖尿病, 14:1-4, 1971
 
5) Burt MG, et al:Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab, 96:1789-1796, 2011
PubMed
6) Stuck AE, et al:Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis, 11:954-963, 1989
PubMed
7) 日本肝臓学会肝炎診療ガイドライン作成委員会:B型肝炎治療ガイドライン [https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b](2020年1月閲覧)
 
8) Limper AH, et al:An official American Thoracic Society statement:Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med, 183:96-128, 2011
PubMed
9) Miller RF, et al:Pneumocystis Species. 「Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases, 9th ed.」 (Bennett JE, et al, eds), 3238-3254, Elsevier, 2019
 
10) Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR Recomm Rep, 49:1-54, 2000
PubMed
P.250 掲載の参考文献
1) Limper AH, et al:Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis, 140:1204-1209, 1989
PubMed
2) 徳田 均:非AIDS 症例におけるニューモシスチス肺炎. 日本胸部臨床, 69:112-123, 2010
Medical*Online
3) Roux A, et al:Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis, 20:1490-1497, 2014
 
4) HIV/AIDS treatment and research information from the US federal government:Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, 2019 [https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf](2019年12月閲覧)
 
5) Martin SI & Fishman JA:Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant, 9 Suppl 4:S227-233, 2009
 
6) Neumann S, et al:Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors:guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 92:433-442, 2013
PubMed
7) Miller RF, et al:Pneumocystis Species. 「Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases, 9th ed」 (Bennett JE, et al eds), 3238-3254, Elsevier, 2019
 
8) Demoruelle MK, et al:Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res, 65:314-323, 2013
PubMed
9) Yale SH & Limper AH:Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome:associated illness and prior corticosteroid therapy. Mayo Clin Proc, 71:5-13, 1996
PubMed
10) 山口牧子, 他:ニューモシスチス肺炎予防のためのスルファメトキサゾール・トリメトプリム投与量の検討. 日本呼吸器学会誌, 6:53-57, 2017
Medical*Online
11) 「ニューモシスチス肺炎のすべて」(ニューモシスチス肺炎研究会/編), 克誠堂出版, 2014
 
12) Solensky R:Drug desensitization. Immunol Allergy Clin North Am, 24:425-443, 2004
PubMed
P.258 掲載の参考文献
1) Berliner N:Approach to the adult with unexplained pancytopenia. UpToDate, 2018
 
2) Piva E, et al:Automated reticulocyte counting:state of the art and clinical applications in the evaluation of erythropoiesis. Clin Chem Lab Med, 48:1369-1380, 2010
PubMed
3) Guyatt GH, et al:Laboratory diagnosis of iron-deficiency anemia:an overview. J Gen Intern Med, 7:145-153, 1992
PubMed
4) Shih AW, et al:Haptoglobin testing in hemolysis:measurement and interpretation. Am J Hematol, 89:443-447, 2014
PubMed
5) Berkman N, et al:EDTA-dependent pseudothrombocytopenia:a clinical study of 18 patients and a review of the literature. Am J Hematol, 36:195-201, 1991
 
6) Briggs C, et al:Assessment of an immature platelet fraction(IPF) in peripheral thrombocytopenia. Br J Haematol, 126:93-99, 2004
PubMed
7) 小池由佳子, 他:網血小板/幼若血小板比率の臨床応用. 日本血栓止血学会誌, 19(4):459-461, 2008
 
8) 「発熱性好中球減少症(FN)診療ガイドライン改訂第2版」(日本臨床腫瘍学会/編), 南江堂, 2017
 
9) 「Wintrobe's Clinical Hematology Thirteenth ed.」(Greer MD, et al, eds), pp19-29, LWW, 2013
 
10) Vetsika EK & Callan M:Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med, 6:1-16, 2004
PubMed
11) Bain BJ:Diagnosis from the blood smear. N Engl J Med, 353:498-507, 2005
PubMed
12) Rosenthal DS:Evaluation of the peripheral blood smear. UpToDate, 2019
 

第5章 消化器・神経病棟のギモン

P.265 掲載の参考文献
1) Takashima K, et al:Kampo medicines induce formula-dependent changes in the intestinal flora of mice. J Trad Med, 29:179-185, 2012
 
2) Allen SJ, et al:Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev, 11:CD003048, 2010
PubMed
3) Goldenberg JZ, et al:Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 5:CD006095, 2013
PubMed
4) van Nood E, et al:Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med, 368:407-415, 2013
PubMed
5) Feher C & Mensa J:A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management. Infect Dis Ther, 5:207-230, 2016
 
6) Zajac AE, et al:A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. Int Forum Allergy Rhinol, 5:524-532, 2015
PubMed
7) Ley RE, et al:Microbial ecology:human gut microbes associated with obesity. Nature, 444:1022-1023, 2006
PubMed
P.266 掲載の参考文献
1) Haastrup PF, et al:Basic Clin Pharmacol Toxicol, 123:114-121, 2018
PubMed
P.271 掲載の参考文献
1) 滝川 一, 他:DDW-J 2004 ワークショップ薬物性肝障害診断基準の提案. 肝臓, 46:85-90, 2005
 
2) Hitzeman N & Belsky K:Appropriate use of polypharmacy for older patients. Am Fam Physician, 87:483-484, 2013
PubMed
3) American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 67:674-694, 2019
 
4) Gallagher P, et al:STOPP(Screening Tool of Older Person's Prescriptions)and START (Screening Tool to Alert doctors to Right Treatment).Consensus validation. Int J Clin Pharmacol Ther, 46:72-83, 2008
 
5) O'Mahony D, et al:STOPP/START criteria for potentially inappropriate prescribing in older people:version 2. Age Ageing, 44:213-218, 2015
 
6) 「高齢者の安全な薬物療法ガイドライン2015」(日本老年医学会/編), メジカルビュー社, 2015
 
7) 厚生労働省:重篤副作用疾患別対応マニュアル 薬物性肝障害, 2008 [http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1i01.pdf](2020年1月閲覧)
 
P.278 掲載の参考文献
1) Spirt MJ, et al:Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse, 26:18-29, 2006
PubMed
2) Rhodes A, et al:Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock:2016. Crit Care Med, 45:486-552, 2017
PubMed
3) M Michael Wolfe, et al:Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders, UpToDate:2014
 
4) Raff T, et al:The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns, 23:313-318, 1997
 
5) Marik PE, et al:Stress ulcer prophylaxis in the new millennium:a systematic review and meta-analysis. Crit Care Med, 38:2222-2228, 2010
PubMed
6) Lanza FL, et al:Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol, 104:728-738, 2009
PubMed
7) Bombardier C et al:Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 343:1520-1528, 2000
PubMed
P.283 掲載の参考文献
1) Medical guidelines for determining prognosis in selected non-cancer diseases. The National Hospice Organization. Hosp J, 11:47-63, 1996
PubMed
2) Mitchell SL:CLINICAL PRACTICE. Advanced Dementia. N Engl J Med, 372:2533-2540, 2015
PubMed
3) Lee SJ, et al:Time lag to benefit after screening for breast and colorectal cancer:meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ, 346:e8441, 2013
PubMed
4) Tang V, et al:Time to benefit for colorectal cancer screening:survival meta-analysis of flexible sigmoidoscopy trials. BMJ, 350:h1662, 2015
PubMed
5) Shaukat A, et al:Long-term mortality after screening for colorectal cancer. N Engl J Med, 369:1106-1114, 2013
PubMed
6) U.S. Preventive Services TASK FORCE:Colorectal Cancer:Screening [https://www.uspreventiveservicestaskforce.org/](2019年12月閲覧)
 
7) 祖父江友孝, 他:有効性評価に基づく大腸がん検診ガイドライン(普及版). 癌と科学療法, 32:901-915, 2005
 
P.292 掲載の参考文献
1) Inouye SK:Delirium in older persons. N Engl J Med, 354:1157-1165, 2006
 
2) Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry, 156:1-20, 1999
PubMed
3) Michaud L, et al:Delirium:guidelines for general hospitals. J Psychosom Res, 62:371-383, 2007
PubMed
4) 井上真一郎, 内富庸介:せん妄の要因と予防. 臨床精神医学, 42:289-297, 2013
Medical*Online
5) Young J, et al:Diagnosis, prevention, and management of delirium:summary of NICE guidance. BMJ, 341:c3704, 2010
PubMed
P.298 掲載の参考文献
1) Shen WK, et al:2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 136:e25-59, 2017
 
2) Quinn J, et al:Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes, Ann Emerg Med, 47:448-454, 2006
PubMed
P.307 掲載の参考文献
1) Fisher RS, et al:Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia, 58:531-542, 2017
PubMed
2) Meldrum BS & Horton RW:Physiology of status epilepticus in primates. Arch Neurol, 28:1-9, 1973
PubMed
3) 「てんかん診療ガイドライン2018」(日本神経学会/監, 「てんかん診療ガイドライン」作成委員会/編), pp77-78, 医学書院, 2018
 
4) Shorvon S & Ferlisi M:The treatment of super-refractory status epilepticus:a critical review of available therapies and a clinical treatment protocol. Brain, 134(Pt 10):2802-2818, 2011
 
5) Brophy GM, Bell R, Claassen J, et al. Neurocritical Care Society Status Epilepticus Guideline Writing Committee:Guidelines for the evaluation and management of status epilepticus. Neurocrit Care, 17:3-23, 2012
PubMed
6) Mazurkiewicz-Beldzinska M, et al:Current treatment of convulsive status epilepticus -a therapeutic protocol and review. Anaesthesiol Intensive Ther, 46:293-300, 2014
PubMed
7) Betjemann JP & Lowenstein DH:Status epilepticus in adults. Lancet Neurol, 14:615-624, 2015
PubMed
8) 大澤真木子:けいれん重積の治療. 脳と発達, 39:185-192, 2007
Medical*Online
9) Wu W, et al:Lorazepam or diazepam for convulsive status epilepticus:A meta-analysis. J Clin Neurosci, 29:133-138, 2016
PubMed
10) Zelano J & Kumlien E:Levetiracetam as alternative stage two antiepileptic drug in status epilepticus:a systematic review. Seizure, 21:233-236, 2012
PubMed
11) Rossetti AO:Which anesthetic should be used in the treatment of refractory status epilepticus ? Epilepsia, 48(Suppl.8):52-55, 2007
 
12) Jacobi J, et al:Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med, 30:119-141, 2002
PubMed
13) Neligan A & Shorvon SD:Frequency and prognosis of convulsive status epilepticus of different causes:a systematic review. Arch Neurol, 67:931-940, 2010
PubMed
14) Sagduyu A, et al:Generalized tonic-clonic status epilepticus:causes, treatment, complications and predictors of case fatality. J Neurol, 245:640-646, 1998
PubMed
P.316 掲載の参考文献
1) 「慢性頭痛の診療ガイドライン2013」(日本神経学会, 日本頭痛学会/監), 医学書院, 2013
 
2) 滝沢 翼, 鈴木則宏:頭痛の分類と診断. 臨牀と研究, 93:1287-1293, 2016
Medical*Online
3) 「国際頭痛分類 第3版」(日本頭痛学会, 国際頭痛分類委員会/訳), 医学書院, 2018
 
4) Detsky ME, et al:Does this patient with headache have a migraine or need neuroimaging? JAMA, 296:1274-1283, 2006
PubMed
5) 「頭痛ダイアリー」(坂井文彦/監), 日本頭痛学会 [http://www.jhsnet.org/pdf/headachediary.pdf](2020年1月閲覧)
 

第6章 研修医室のギモン

P.324 掲載の参考文献
1) Jacobson TA:Toward "pain-free" statin prescribing:clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc, 83:687-700, 2008
PubMed
1) 「読む技術 論文の価値を見抜くための基礎知識」(トリーシャ・グリーンハーフ/著), 日経メディカル, 2016
 
2) 「医学文献ユーザーズガイド 第3版」(相原守夫/訳), 中外医学社, 2018
 
2) Salami JA, et al:National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013:Insights From the Medical Expenditure Panel Survey. JAMA Cardiol, 2:56-65, 2017
PubMed
3) FDA Adverse Events Reporting System(FAERS) Public Dashboard. [https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard](2019年12月閲覧)
 
4) Sackett DL, et al:Evidence based medicine:what it is and what it isn't. BMJ, 312:71-72, 1996
PubMed
5) Sackett DL:Evidence-based medicine. Semin Perinatol, 21:3-5, 1997
PubMed
6) ASCEND Study Collaborative Group:Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med, 379:1529-1539, 2018
 
P.337 掲載の参考文献
1) Carlstrom M & Larsson SC:Coffee consumption and reduced risk of developing type 2 diabetes:a systematic review with meta-analysis. Nutr Rev, 76:395-417, 2018
PubMed
2) Xie C, et al:Coffee consumption and risk of hypertension:a systematic review and dose-response meta-analysis of cohort studies. J Hum Hypertens, 32:83-93, 2018
PubMed
3) Chen YP, et al:A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr, 38:2552-2557, 2018
 
4) Yu C, et al:An updated dose-response meta-analysis of coffee consumption and liver cancer risk. Sci Rep, 6:37488, 2016
PubMed
5) Sartini M, et al:Coffee Consumption and Risk of Colorectal Cancer:A Systematic Review and Meta-Analysis of Prospective Studies. Nutrients, 11:694, 2019
PubMed
6) Xie Y, et al:Coffee consumption and the risk of lung cancer:an updated meta-analysis of epidemiological studies. Eur J Clin Nutr, 70:199-206, 2016
PubMed
7) Ding M, et al:Long-term coffee consumption and risk of cardiovascular disease:a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation, 129:643-659, 2014
 
8) Abe SK, et al:Coffee consumption and mortality in Japanese men and women:A pooled analysis of eight population-based cohort studies in Japan (Japan Cohort Consortium). Prev Med, 123:270-277, 2019
PubMed
9) Doepker C, et al:Key Findings and Implications of a Recent Systematic Review of the Potential Adverse Effects of Caffeine Consumption in Healthy Adults, Pregnant Women, Adolescents, and Children. Nutrients, 10:pii:E1536, 2018
 
10) Milanez S:Adverse Health Effects of Caffeine:Review and Analysis of Recent Human and Animal Research, 2011 [http://www.nationalacademies.org/hmd/~/media/Files/Activity%20Files/Nutrition/PotentialEffectsofCaffeine/caffeineORNLreport.pdf](2020年1月閲覧)
 
P.338 掲載の参考文献
[https://lpi.oregonstate.edu/mic/food-beverages/coffee](2020年1月閲覧)
 
P.344 掲載の参考文献
1) 大川二郎:腫瘍マーカーの見方. 「臨床検査のガイドライン2005/2006」(日本臨床検査医学会包括医療検討委員会, 厚生労働省/編), 日本臨床検査医学会, 2005
 
2) Schroder FH, et al:Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360:1320-1328, 2009
 
3) Andriole GL, et al:Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 360:1310-1319, 2009
 
4) Djulbegovic M, et al:Screening for prostate cancer:systematic review and meta-analysis of randomised controlled trials. BMJ, 341:c4543, 2010
PubMed
5) Buys SS, et al:Effect of screening on ovarian cancer mortality:the Prostate, Lung, Colorectal and Ovarian(PLCO)Cancer Screening Randomized Controlled Trial. JAMA, 305:2295-2303, 2011
PubMed
6) Bruinvels DJ, et al:Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg, 219:174-182, 1994
PubMed
7) Bast RC Jr, et al:2000 update of recommendations for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 19:1865-1878, 2001
 
P.352 掲載の参考文献
1) 基礎研究x内科医:プレゼンが得意になる! 見やすいパワーポイントの作り方, 2019 [http://cork31-naikai.com/?p=797](2020年1月閲覧)
 
2) 「やるべきことが見えてくる研究者の仕事術」(島岡 要/著), 羊土社, 2009
 
3) 「はじめての学会発表 症例報告」(國松淳和/著), 中山書店, 2016
 
4) 「理系のための研究生活ガイド 第2版」(坪田一男/著), 講談社, 2010
 
5) 「改訂版 症例報告, 何をどうやって準備する? 流れがわかる学会発表・論文作成HowTo」 (佐藤雅昭/著), メディカルレビュー社, 2011
 
6) Bourne PE:Ten simple rules for making good oral presentations. PLoS Comput Biol, 3:e77, 2007
PubMed
P.357 掲載の参考文献
1) Baile WF, et al:SPIKES-A six-step protocol for delivering bad news:application to the patient with cancer. Oncologist, 5:302-311, 2000
 
2) 「死ぬ瞬間 死とその過程について」(エリザベス・キューブラー・ロス/著), 中央公論社, 2001
 

書評

最近チェックした商品履歴

Loading...